May 29, 2012The Prostate

Angiotensin‐(1‐7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt‐1

View Full Paper

Ask AI

Bookmark

Why the study?

Does Angiotensin-(1-7) reduce tumor growth and angiogenesis in athymic mice with human prostate cancer xenografts?

Structured PICO

Does Angiotensin-(1-7) reduce tumor growth and angiogenesis in athymic mice with human prostate cancer xenografts?

Population

Athymic mice with human LNCaP prostate cancer cell xenografts

Intervention

Angiotensin-(1-7) [Ang-(1-7)] administered for 54 days

Comparator

Saline

Outcome

Tumor growth (volume and wet weight) and angiogenesissurrogate

Angiotensin-(1-7) demonstrates anti-proliferative and anti-angiogenic effects in a prostate cancer xenograft model, highlighting its potential as a novel therapeutic agent.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Ang-(1-7) shows anti-tumor activity in prostate xenografts; leaves open translation to human therapy.

Cite This Study

Krishnan et al. (2012) studied this question.

synapsesocial.com/papers/6a90ff292684f6cf7b7a747c https://doi.org/10.1002/pros.22540

View Full Paper

Ask AI

Bookmark

Angiotensin‐(1‐7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt‐1

Structured PICO

Discussion

Implication

Cite This Study

Angiotensin‐(1‐7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt‐1

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider